Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center , Portland, OR

Steven Kempers
Minnesota Clinical Study Center , New Brighton, MN

Todd Schlesinger
Clinical Research Center of the Carolinas, Charleston, SC

Edward Lain
Austin Institute for Clinical Research, Pflugerville, TX

Hui Wang
Athenex, Inc., Buffalo, NY

David Cutler
Athenex, Inc., Buffalo, NY

Mark Lebwohl
Icahn School of Medicine at Mount Sinai, New York, NY

Jane Fang
Athenex, Inc., Buffalo, NY

Rudolf Kwan
Athenex, Inc., Buffalo, NY

Keywords

Skin Cancer, Actinic Keratosis, Src Kinase Inhibitor, Tirbanbulin

Abstract

Abstract not available.

References

References not available.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.121

Article Details

How to Cite
Blauvelt, A., Kempers, S., Schlesinger, T., Lain, E., Wang, H., Cutler, D., Lebwohl, M., Fang, J., & Kwan, R. (2020). Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine, 4(6), s121. https://doi.org/10.25251/skin.4.supp.121
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 11 > >>